A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 17 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Events
  • Panel discussion: Jayasree K. Iyer joins healthcare panel at J....
Panel discussion - Event date: 22 Mar 2022
Share

Jayasree K. Iyer joins healthcare panel at J.P. Morgan's Global ESG Conference

Access to Medicine Foundation CEO Jayasree K. Iyer is set to speak at the 7th annual J.P. Morgan Global ESG Conference on 22 March. She will join a panel discussion on the topic, "Healthcare: Balancing ESG Opportunities and Risks".

Explore further

Event

The Evolving Needs of Women’s Sexual and Reproductive Health

Access to Medicine Foundation CEO Jayasree K. Iyer is set to speak at an event in London on the morning of Thursday 17 March 2022, addressing the topic: “A Period of Change: The Evolving Needs of Women’s Sexual and Reproductive Health”.
Publication

STAT: Global investors must support pharma solidarity and collaboration in response to COVID19

Writing in STAT, the authors call on investor colleagues to step up their engagement activities and ask all governments and pharmaceutical companies to fully embrace the principles of collaboration and solidarity in the global response to COVID-19. By Sacha Sadan, Yo Takatsuki and Damiano de Felice.
Feature

How we work with investors

Numerous investors already work with the Access to Medicine Foundation to improve their knowledge of how pharmaceutical companies manage risks and opportunities related to access-to-medicine and antimicrobial resistance (AMR). As of January 2021, 100+ investors – together managing assets of more than USD 18 trillion – have signed the Access to Medicine Index Investor Statement and committed to using the research of the Access to Medicine Foundation in their investment analysis and engagements with companies.

Get in touch

Back to top |